You are here

ANDROBIOSYS, INC.

Company Information
Address
875 Ellicott St
BUFFALO, NY 14203-1070
United States


http://www.androbiosys.com

Information

UEI: N/A

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Circulating Prostate Cancer Progenitor Cell Assay Development

    Amount: $747,553.00

    The technical objectives of this Phase II project are to identify unique biomarkers and produce molecular, antibody and peptide reagents that are specific for human prostate cancer progenitor stem cel ...

    STTRPhase II2011Department of Defense Army
  2. Platelet-based Nanoparticle Therapy for Prostate Cancer

    Amount: $999,642.00

    The goal of this Phase II proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The ...

    SBIRPhase II2010Department of Health and Human Services National Institutes of Health
  3. Vascular Targeting for Imaging and Treatment of Benign Prostatic Hyperplasia

    Amount: $128,052.00

    DESCRIPTION (provided by applicant): Benign Prostatic Hyperplasia/Hypertrophy is a major health problem in the United States, with one-in-three men having urologic problems. Currently available treatm ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  4. Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ

    Amount: $139,945.00

    DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved p ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  5. Circulating Prostate Cancer Progenitor Cell Assay Development

    Amount: $96,765.00

    This Phase I contract proposal will evaluate and identify markers associated with prostate cancer progenitor stem cells, that differentiate these cells from adult tissue stem cells and benign prostate ...

    STTRPhase I2008Department of Defense Army
  6. PLATELET-BASED NANOPARTICLE THERAPY FOR PROSTATE CANCER

    Amount: $149,994.00

    The goal of this proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government